Journal
CLINICAL INFECTIOUS DISEASES
Volume 55, Issue -, Pages S127-S131Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cis358
Keywords
-
Categories
Funding
- Optimer Pharmaceuticals, Inc.
- Optimer Pharmaceuticals
Ask authors/readers for more resources
Fidaxomicin was recently approved for the treatment of Clostridium difficile infection. It inhibits transcription by bacterial RNA polymerase. Because transcription is a multistep process, experiments were conducted in which fidaxomicin was added at different stages of transcriptional initiation to identify the blocked step. DNA footprinting experiments were also conducted to further elucidate the stage inhibited. Fidaxomicin blocks initiation only if added before the formation of the open promoter complex, in which the template DNA strands have separated but RNA synthesis has not yet begun. Binding of fidaxomicin precludes the initial separation of DNA strands that is prerequisite to RNA synthesis. These studies show that it has a mechanism distinct from that of elongation inhibitors, such as streptolydigin, and from the transcription initiation inhibitors myxopyronin and the rifamycins.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available